All AstraZeneca articles
-
NewsFDA marks progress in implementing real-time clinical trials
Advances agency’s goal in facilitating continuous trials, aimed at accelerating promising therapies.
-
NewsFDA approves Breztri as first triple-therapy inhaler for asthma
AstraZeneca’s Breztri Aerosphere has become the first fixed-dose triple-combination inhaler approved by the FDA for asthma maintenance treatment in adults and adolescents aged 12 and older, addressing unmet needs for approximately 13.5 million US patients uncontrolled on dual therapies.
-
NewsAstraZeneca’s Imfinzi plus chemotherapy earns CHMP nod in gastric cancer
If approved, the regimen would become the first immunotherapy-based perioperative therapy for adults with early gastric and gastroesophageal cancers in Europe.
-
NewsAstraZeneca makes $15bn manufacturing investment in China
Landmark, decade-long investment plan aims to support the pharma company’s 2030 revenue objective of $80 billion.
-
NewsEndotoxins research supports recombinant reagent use for pharma QC
Replacing LAL reagents with animal-free alternatives addresses industry commitments to improve QC practices’ ethics and sustainability.
-
NewsAstraZeneca hires Rick Suarez to lead its biopharma efforts in the US
His appointment comes as the pharma company AstraZeneca seeks to hit $80 billion revenue target by 2030.
-
News
US oral GLP-1 first as Novo Nordisk launches Wegovy pill
The obesity drug’s new formulation gains an important opportunity to define the market before regulators finish assessing Lilly’s rival orforglipron.
-
NewsAstraZeneca and Daiichi’s Enhertu wins first-in-decade US oncology approval
FDA approval of the drug in combination with Perjeta initiates a $150 million milestone payment to Daiichi Sankyo from AstraZeneca under their joint collaboration.
-
News
AstraZeneca furthers US manufacturing commitment with $2bn Maryland investment
The move is part of biopharma's $50 billion pledge to US medicines manufacturing and R&D.
-
News
Pfizer’s Metsera hunger sees it beat Novo Nordisk’s obesity biopharma offer
The deal puts Pfizer’s plans to acquire the US firm, and a portfolio that includes injectable GLP-1 drugs, back on track.
-
NewsAstraZeneca seals obesity deal as Pfizer-Novo Nordisk battle for Metsera
After Wegovy and Zepbound's success, competition for the next potential weight loss blockbuster heats up.
-
NewsAlexion wins EU label expansion for kinase inhibitor Koselugo
Approval provides continuity of care into adulthood for patients with neurofibromatosis type 1 (NF1) using Koselugo (selumetinib) to manage symptoms.
-
NewsUV contamination control robot shows pharma cleanroom promise
Efficacy research supports the widespread use of autonomous UVC disinfection for microbial surface decontamination, say AstraZeneca microbiology experts.
-
News
AstraZeneca doubles Lokelma production at its Texas facility
The pharma company invested $445m to expand its Coppell site.
-
NewsAstraZeneca increases scope of new US API manufacturing facility by $500m
The company will now put a total of $4.5 billion into the Virginia site, expanding its remit to include active pharmaceutical ingredients for cancer drugs.
-
NewsAstraZeneca and Daiichi's Datroway gets phase III breast cancer boost
Companies’ first-line ambitions for the antibody drug conjugate buoyed by the TROPION-Breast02 clinical trial.
-
ArticleMicrobiology/RMM In-Depth Focus 2025
This in-depth focus features articles on rapid microbiological methods, quality control, and using AI to read agar plates.
-
ArticleEuropean Pharmaceutical Review Issue 3 2025
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
-
News
Pharma's UK dissatisfaction mounts as Merck & Co axes $1.3bn expansion
Biotech and research investments from Lilly and AstraZeneca also put on hold as pricing row rumbles on.
-
NewsRoche touts ‘best-in-disease’ potential for anti-hypertensive zilebesiran
While AstraZeneca’s first-in-class candidate baxdrostat marks phase III hypertension win at ESC 2025.